 <h1>Gris-PEG Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>griseofulvin</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about griseofulvin. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Gris-PEG.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to griseofulvin: oral suspension, oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, griseofulvin (the active ingredient contained in Gris-PEG) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking griseofulvin:</p><p>
<i>More common</i>
</p><ul>
<li>Blistering, peeling, or loosening of the skin</li>
<li>chills</li>
<li>cough</li>
<li>diarrhea</li>
<li>fever</li>
<li>itching</li>
<li>joint or muscle pain</li>
<li>red, irritated eyes</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots in the mouth or on the lips</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Confusion</li>
<li>increased sensitivity of the skin to sunlight</li>
<li>skin rash, hives, or itching</li>
<li>soreness or irritation of the mouth or tongue</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Black, tarry stools</li>
<li>chest pain</li>
<li>cloudy urine</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>numbness, tingling, pain, or weakness in the hands or feet</li>
<li>painful or difficult urination</li>
<li>shortness of breath</li>
<li>swollen glands</li>
<li>unusual bleeding or bruising</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Abdominal or stomach pain</li>
<li>burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings</li>
<li>clay-colored stools</li>
<li>dark urine</li>
<li>dizziness</li>
<li>headache</li>
<li>loss of appetite</li>
<li>nausea</li>
<li>unpleasant breath odor</li>
<li>vomiting of blood</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of griseofulvin may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Hives or welts</li>
<li>redness of the skin</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Trouble with sleeping</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Heartburn</li>
<li>pain or discomfort in the chest, upper stomach, or throat</li>
<li>sleeplessness</li>
<li>unable to sleep</li>
<li>white patches in the mouth or throat or on the tongue</li>
<li>white patches with diaper rash</li>
</ul><p>
<!-- end oral suspension, oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to griseofulvin: compounding powder, oral capsule, oral suspension, oral tablet</i></p><h3>Nervous system</h3><p>Headache was sometimes severe and usually disappeared during continued therapy.</p>
<p></p>
<p>Neuropathy and paresthesia have been reported in a few cases of long-term therapy with this drug.  In 1 woman, paresthesia reportedly developed in the fingers and feet after 6 months of therapy.  Neuropathy progressed for 4 months after the drug was discontinued but resolved 8 months after therapy was discontinued.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Headache (up to 15%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Impaired coordination, peripheral neuropathy, confusion, dizziness, drowsiness, taste sensation changes</p>
<p><b>Frequency not reported</b>: Peripheral neuritis, lethargy, mental confusion, impairment of performance of routine activities/efforts, vertigo, neuropathy, paresthesia of the hands and feet<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>A moderate but inconsistent increase of fecal protoporphyrins has been observed when this drug was used for a prolonged duration.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Diarrhea, nausea, vomiting, gastric discomfort</p>
<p><b>Frequency not reported</b>: Heartburn, flatulence, gastrointestinal bleeding, epigastric distress, oral thrush, increased fecal protoporphyrins<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>At least 1 reported case of toxic epidermal necrolysis resulted in death.</p>
<p></p>
<p>Fixed-drug eruptions have been verified by rechallenge.</p>
<p></p>
<p>A patient with Hailey-Hailey disease (chronic benign familial pemphigus) experienced a widespread bullous eruption due to this drug.<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Toxic epidermal necrolysis, erythema multiforme, photosensitivity (on exposure to intense natural/artificial sunlight)</p>
<p><b>Rare</b> (0.01% to 0.1%): Bullous reactions (including Lyell's syndrome), urticarial reactions, skin rashes, severe angioedema</p>
<p><b>Frequency not reported</b>: Cold and warm urticaria, erythema eruptions, vesicular eruptions, morbilliform eruptions, fixed-drug eruptions, lesions (on sun-exposed areas), bullous eruption</p>
<p><b>Postmarketing reports</b>: Severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), erythema multiforme<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Uncommon</b> (0.1% to 1%): Insomnia, irritability<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Uncommon</b> (0.1% to 1%): Anorexia</p>
<p><b>Frequency not reported</b>: Thirst, exacerbation of porphyria<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Rare</b> (0.01% to 0.1%): Serum sickness syndromes</p>
<p><b>Frequency not reported</b>: Hypersensitivity reactions (e.g., skin rashes, urticaria, erythema multiforme/erythema multiforme-like drug reactions, angioneurotic edema)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Rare</b> (0.01% to 0.1%): Hepatotoxicity</p>
<p><b>Very rare</b> (less than 0.01%): Altered/elevated liver function tests, intrahepatic cholestasis, hepatitis</p>
<p><b>Frequency not reported</b>: Elevated liver enzymes, hyperbilirubinemia</p>
<p><b>Postmarketing reports</b>: Jaundice, elevated AST, elevated ALT, elevated bilirubin<sup>[Ref]</sup></p><p>Liver function tests were elevated to greater than 3 times the upper limit of normal.<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Rare</b> (0.01% to 0.1%): Leukopenia, neutropenia, anemia</p>
<p><b>Frequency not reported</b>: Coagulopathy<sup>[Ref]</sup></p><p>Leukopenia, neutropenia, and anemia generally resolved when therapy was stopped.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Rare</b> (0.01% to 0.1%): Precipitation of systemic lupus erythematosus, lupus-like syndromes, exacerbation of existing lupus</p>
<p><b>Frequency not reported</b>: Drug-induced myositis<sup>[Ref]</sup></p><p>At least 1 fatal case of systemic lupus erythematosus exacerbation occurred after ingestion of about 1 g of this drug.<sup>[Ref]</sup></p><h3>Renal</h3><p>A patient developed interstitial nephritis after 1 year of therapy.  The patient presented with renal insufficiency, hematuria, pyuria, eosinophiluria, and anemia.  Renal function returned to normal after 1 year.<sup>[Ref]</sup></p><p><b>Rare</b> (0.01% to 0.1%): Nephrosis</p>
<p><b>Frequency not reported</b>: Interstitial nephritis<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Rare</b> (0.01% to 0.1%): Proteinuria, menstrual irregularities</p>
<p><b>Frequency not reported</b>: Albuminuria (without evidence of renal dysfunction)<sup>[Ref]</sup></p><h3>Other</h3><p>A disulfiram-like reaction (including flushing, nausea, vomiting, diarrhea, paresthesia of the extremities) occurred in 1 patient who ingested this drug with alcohol.<sup>[Ref]</sup></p><p><b>Frequency not reported</b>: Fatigue, fever, disulfiram-like reaction<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Grifulvin V (griseofulvan)." Ortho Pharmaceuticals, Raritan, NJ.  (1992):</p><p id="ref_2">2. Gupta AK,  Ryder JE "The use of oral antifungal agents to treat onychomycosis." Dermatol Clin 21 (2003): 469-79, vi</p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_5">5. Lecky BR "Griseofulvin-induced neuropathy." Lancet 1 (1990): 230-1</p><p id="ref_6">6. "Product Information. Fulvicin P/G (griseofulvin)." Schering Laboratories, Kenilworth, NJ. </p><p id="ref_7">7. Taylor B, Duffill M "Toxic epidermal necrolysis from griseofulvin." J Am Acad Dermatol 19 (1988): 565-6</p><p id="ref_8">8. Feinstein A, Sofer E, Trau H, Schewach-Millet M "Urticaria and fixed drug eruption in a patient treated with griseofulvin." J Am Acad Dermatol 10 (1984): 915-7</p><p id="ref_9">9. Meffert JJ, Davis BM, Campbell JC "Bullous drug eruption to griseofulvin in a man with hailey-hailey disease." Cutis 56 (1995): 279-80</p><p id="ref_10">10. Rustin MH, Bunker CB, Dowd PM, Robinson TW "Erythema multiforme due to griseofulvin." Br J Dermatol 120 (1989): 455-8</p><p id="ref_11">11. Mion G, Verdon R, Le Gulluche YL, Carstein H, Garcia A, Guilbaud J "Fatal toxic epidermal necrolysis after griseofulvin." Lancet 2 (1989): 1331</p><p id="ref_12">12. Boudghene-Stambouli O, Merad-Boudia A "Fixed drug eruption induced by griseofulvin." Dermatologica 179 (1989): 92-3</p><p id="ref_13">13. Miyagawa S, Sakamoto K "Adverse reaction to griseofulvin in patients with circulating anti-ssa/ro and ssb/la autoantibodies." Am J Med 87 (1989): 99-102</p><p id="ref_14">14. Debruyne D, Coquerel A "Pharmacokinetics of antifungal agents in onychomycoses." Clin Pharmacokinet 40 (2001): 441-72</p><p id="ref_15">15. Davidson BK "Myositis associated with griseofulvin therapy." Am Fam Physician 52 (1995): 1277</p><p id="ref_16">16. Madhok R, Zoma A, Capell H "Fatal exacerbation of systemic lupus erythematosus after treatment with griseofulvin." Br Med J (Clin Res Ed) 291 (1985): 249-50</p><p id="ref_17">17. Miyagawa S, Okuchi T, Shiomi Y, Sakamoto K "Subacute cutaneous lupus erythematosus lesions precipitated by griseofulvin." J Am Acad Dermatol 21 (1989): 343-6</p><p id="ref_18">18. Fett DL, Vukov LF "An unusual case of severe griseofulvin alcohol interaction." Ann Emerg Med 24 (1994): 95-7</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Gris-PEG (griseofulvin)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>5 Reviews</li>
<li>Generic Availability</li>
<li>Drug class: miscellaneous antifungals</li>
<li>FDA Alerts (1)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Advanced Reading</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Grifulvin V, Fulvicin P/G, Fulvicin U/F</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Onychomycosis, Toenail</li>
<li>Dermatophytosis</li>
<li>Onychomycosis, Fingernail</li>
<li>Tinea Barbae</li>
<li data-more-config-id="list-data-resources-conditions">... +4 more</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to griseofulvin: compounding powder, oral capsule, oral suspension, oral tablet</i></p><h3>Nervous system</h3><p>Headache was sometimes severe and usually disappeared during continued therapy.</p><p></p><p>Neuropathy and paresthesia have been reported in a few cases of long-term therapy with this drug.  In 1 woman, paresthesia reportedly developed in the fingers and feet after 6 months of therapy.  Neuropathy progressed for 4 months after the drug was discontinued but resolved 8 months after therapy was discontinued.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Headache (up to 15%)</p><p><b>Uncommon</b> (0.1% to 1%): Impaired coordination, peripheral neuropathy, confusion, dizziness, drowsiness, taste sensation changes</p><p><b>Frequency not reported</b>: Peripheral neuritis, lethargy, mental confusion, impairment of performance of routine activities/efforts, vertigo, neuropathy, paresthesia of the hands and feet<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>A moderate but inconsistent increase of fecal protoporphyrins has been observed when this drug was used for a prolonged duration.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Diarrhea, nausea, vomiting, gastric discomfort</p><p><b>Frequency not reported</b>: Heartburn, flatulence, gastrointestinal bleeding, epigastric distress, oral thrush, increased fecal protoporphyrins<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>At least 1 reported case of toxic epidermal necrolysis resulted in death.</p><p></p><p>Fixed-drug eruptions have been verified by rechallenge.</p><p></p><p>A patient with Hailey-Hailey disease (chronic benign familial pemphigus) experienced a widespread bullous eruption due to this drug.<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Toxic epidermal necrolysis, erythema multiforme, photosensitivity (on exposure to intense natural/artificial sunlight)</p><p><b>Rare</b> (0.01% to 0.1%): Bullous reactions (including Lyell's syndrome), urticarial reactions, skin rashes, severe angioedema</p><p><b>Frequency not reported</b>: Cold and warm urticaria, erythema eruptions, vesicular eruptions, morbilliform eruptions, fixed-drug eruptions, lesions (on sun-exposed areas), bullous eruption</p><p><b>Postmarketing reports</b>: Severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), erythema multiforme<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Uncommon</b> (0.1% to 1%): Insomnia, irritability<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Uncommon</b> (0.1% to 1%): Anorexia</p><p><b>Frequency not reported</b>: Thirst, exacerbation of porphyria<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Rare</b> (0.01% to 0.1%): Serum sickness syndromes</p><p><b>Frequency not reported</b>: Hypersensitivity reactions (e.g., skin rashes, urticaria, erythema multiforme/erythema multiforme-like drug reactions, angioneurotic edema)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Rare</b> (0.01% to 0.1%): Hepatotoxicity</p><p><b>Very rare</b> (less than 0.01%): Altered/elevated liver function tests, intrahepatic cholestasis, hepatitis</p><p><b>Frequency not reported</b>: Elevated liver enzymes, hyperbilirubinemia</p><p><b>Postmarketing reports</b>: Jaundice, elevated AST, elevated ALT, elevated bilirubin<sup>[Ref]</sup></p><p>Liver function tests were elevated to greater than 3 times the upper limit of normal.<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Rare</b> (0.01% to 0.1%): Leukopenia, neutropenia, anemia</p><p><b>Frequency not reported</b>: Coagulopathy<sup>[Ref]</sup></p><p>Leukopenia, neutropenia, and anemia generally resolved when therapy was stopped.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Rare</b> (0.01% to 0.1%): Precipitation of systemic lupus erythematosus, lupus-like syndromes, exacerbation of existing lupus</p><p><b>Frequency not reported</b>: Drug-induced myositis<sup>[Ref]</sup></p><p>At least 1 fatal case of systemic lupus erythematosus exacerbation occurred after ingestion of about 1 g of this drug.<sup>[Ref]</sup></p><h3>Renal</h3><p>A patient developed interstitial nephritis after 1 year of therapy.  The patient presented with renal insufficiency, hematuria, pyuria, eosinophiluria, and anemia.  Renal function returned to normal after 1 year.<sup>[Ref]</sup></p><p><b>Rare</b> (0.01% to 0.1%): Nephrosis</p><p><b>Frequency not reported</b>: Interstitial nephritis<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Rare</b> (0.01% to 0.1%): Proteinuria, menstrual irregularities</p><p><b>Frequency not reported</b>: Albuminuria (without evidence of renal dysfunction)<sup>[Ref]</sup></p><h3>Other</h3><p>A disulfiram-like reaction (including flushing, nausea, vomiting, diarrhea, paresthesia of the extremities) occurred in 1 patient who ingested this drug with alcohol.<sup>[Ref]</sup></p><p><b>Frequency not reported</b>: Fatigue, fever, disulfiram-like reaction<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Grifulvin V (griseofulvan)." Ortho Pharmaceuticals, Raritan, NJ.  (1992):</p><p id="ref_2">2. Gupta AK,  Ryder JE "The use of oral antifungal agents to treat onychomycosis." Dermatol Clin 21 (2003): 469-79, vi</p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_5">5. Lecky BR "Griseofulvin-induced neuropathy." Lancet 1 (1990): 230-1</p><p id="ref_6">6. "Product Information. Fulvicin P/G (griseofulvin)." Schering Laboratories, Kenilworth, NJ. </p><p id="ref_7">7. Taylor B, Duffill M "Toxic epidermal necrolysis from griseofulvin." J Am Acad Dermatol 19 (1988): 565-6</p><p id="ref_8">8. Feinstein A, Sofer E, Trau H, Schewach-Millet M "Urticaria and fixed drug eruption in a patient treated with griseofulvin." J Am Acad Dermatol 10 (1984): 915-7</p><p id="ref_9">9. Meffert JJ, Davis BM, Campbell JC "Bullous drug eruption to griseofulvin in a man with hailey-hailey disease." Cutis 56 (1995): 279-80</p><p id="ref_10">10. Rustin MH, Bunker CB, Dowd PM, Robinson TW "Erythema multiforme due to griseofulvin." Br J Dermatol 120 (1989): 455-8</p><p id="ref_11">11. Mion G, Verdon R, Le Gulluche YL, Carstein H, Garcia A, Guilbaud J "Fatal toxic epidermal necrolysis after griseofulvin." Lancet 2 (1989): 1331</p><p id="ref_12">12. Boudghene-Stambouli O, Merad-Boudia A "Fixed drug eruption induced by griseofulvin." Dermatologica 179 (1989): 92-3</p><p id="ref_13">13. Miyagawa S, Sakamoto K "Adverse reaction to griseofulvin in patients with circulating anti-ssa/ro and ssb/la autoantibodies." Am J Med 87 (1989): 99-102</p><p id="ref_14">14. Debruyne D, Coquerel A "Pharmacokinetics of antifungal agents in onychomycoses." Clin Pharmacokinet 40 (2001): 441-72</p><p id="ref_15">15. Davidson BK "Myositis associated with griseofulvin therapy." Am Fam Physician 52 (1995): 1277</p><p id="ref_16">16. Madhok R, Zoma A, Capell H "Fatal exacerbation of systemic lupus erythematosus after treatment with griseofulvin." Br Med J (Clin Res Ed) 291 (1985): 249-50</p><p id="ref_17">17. Miyagawa S, Okuchi T, Shiomi Y, Sakamoto K "Subacute cutaneous lupus erythematosus lesions precipitated by griseofulvin." J Am Acad Dermatol 21 (1989): 343-6</p><p id="ref_18">18. Fett DL, Vukov LF "An unusual case of severe griseofulvin alcohol interaction." Ann Emerg Med 24 (1994): 95-7</p><h2>More about Gris-PEG (griseofulvin)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>5 Reviews</li>
<li>Generic Availability</li>
<li>Drug class: miscellaneous antifungals</li>
<li>FDA Alerts (1)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Advanced Reading</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Onychomycosis, Toenail</li>
<li>Dermatophytosis</li>
<li>Onychomycosis, Fingernail</li>
<li>Tinea Barbae</li>
<li data-more-config-id="list-data-resources-conditions">... +4 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>